Home > Oncology > SABCS 2021 > Basic and Translational Research > BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy

BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy

Presented By
Dr Anton Safonov, Memorial Sloan-Kettering Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
An analysis of germline-somatic interactions in breast-cancer tumours revealed novel associations relevant to the disease’s progression and treatment resistance. For example, carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors plus endocrine therapy. Germline genetic alterations are established mediators of breast carcinogenesis, often giving rise to specific forms of genomic instability. BRCA1/2 pathogenic variants are representative of this phenomenon through their induction of homologous recombination deficiency. While specific patterns of genomic instability may sensitise cancers to therapies such as Poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum chemotherapy, their implications for lineage-directed therapies, such as endocrine therapy or CDK4/6 inhibitors , are unknown. Therefore, Dr Anton Safonov (Memorial Sloan-Kettering Cancer C...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on